307 related articles for article (PubMed ID: 16497417)
1. Targeting of HIV-1 Tat traffic and function by transduction-competent single chain antibodies.
Theisen DM; Pongratz C; Wiegmann K; Rivero F; Krut O; Krönke M
Vaccine; 2006 Apr; 24(16):3127-36. PubMed ID: 16497417
[TBL] [Abstract][Full Text] [Related]
2. Protein transduction domains of HIV-1 and SIV TAT interact with charged lipid vesicles. Binding mechanism and thermodynamic analysis.
Ziegler A; Blatter XL; Seelig A; Seelig J
Biochemistry; 2003 Aug; 42(30):9185-94. PubMed ID: 12885253
[TBL] [Abstract][Full Text] [Related]
3. Heparin binding by the HIV-1 tat protein transduction domain.
Hakansson S; Jacobs A; Caffrey M
Protein Sci; 2001 Oct; 10(10):2138-9. PubMed ID: 11567105
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of HIV-Tat protein transduction domain.
Yoon JS; Jung YT; Hong SK; Kim SH; Shin MC; Lee DG; Shin WS; Min WS; Paik SY
J Microbiol; 2004 Dec; 42(4):328-35. PubMed ID: 15650690
[TBL] [Abstract][Full Text] [Related]
5. H. saimiri tyrosine-kinase interacting protein inhibits Tat function: a prototypic strategy for restricting HIV-1-induced cytopathic effects in immune cells.
Raymond AD; Hasham M; Tsygankov AY; Henderson EE
Virology; 2006 Sep; 352(2):253-67. PubMed ID: 16780912
[TBL] [Abstract][Full Text] [Related]
6. The cationic cell-penetrating peptide CPP(TAT) derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: optical, biophysical, and metabolic evidence.
Ziegler A; Nervi P; Dürrenberger M; Seelig J
Biochemistry; 2005 Jan; 44(1):138-48. PubMed ID: 15628854
[TBL] [Abstract][Full Text] [Related]
7. The Tat/TAR-dependent phosphorylation of RNA polymerase II C-terminal domain stimulates cotranscriptional capping of HIV-1 mRNA.
Zhou M; Deng L; Kashanchi F; Brady JN; Shatkin AJ; Kumar A
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12666-71. PubMed ID: 14569024
[TBL] [Abstract][Full Text] [Related]
8. Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo.
Kim D; Jeon C; Kim JH; Kim MS; Yoon CH; Choi IS; Kim SH; Bae YS
Exp Cell Res; 2006 May; 312(8):1277-88. PubMed ID: 16466653
[TBL] [Abstract][Full Text] [Related]
9. The binding affinity of double-stranded RNA motifs to HIV-1 Tat protein affects transactivation and the neutralizing capacity of anti-Tat antibodies elicited after intranasal immunization.
Partidos CD; Hoebeke J; Moreau E; Chaloin O; Tunis M; Belliard G; Briand JP; Desgranges C; Muller S
Eur J Immunol; 2005 May; 35(5):1521-9. PubMed ID: 15789358
[TBL] [Abstract][Full Text] [Related]
10. A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition.
Hamy F; Brondani V; Flörsheimer A; Stark W; Blommers MJ; Klimkait T
Biochemistry; 1998 Apr; 37(15):5086-95. PubMed ID: 9548739
[TBL] [Abstract][Full Text] [Related]
11. The TAR hairpin of human immunodeficiency virus type 1 can be deleted when not required for Tat-mediated activation of transcription.
Das AT; Harwig A; Vrolijk MM; Berkhout B
J Virol; 2007 Jul; 81(14):7742-8. PubMed ID: 17494072
[TBL] [Abstract][Full Text] [Related]
12. Protein transduction domains fused to virus receptors improve cellular virus uptake and enhance oncolysis by tumor-specific replicating vectors.
Kühnel F; Schulte B; Wirth T; Woller N; Schäfers S; Zender L; Manns M; Kubicka S
J Virol; 2004 Dec; 78(24):13743-54. PubMed ID: 15564483
[TBL] [Abstract][Full Text] [Related]
13. Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins.
Desfosses Y; Solis M; Sun Q; Grandvaux N; Van Lint C; Burny A; Gatignol A; Wainberg MA; Lin R; Hiscott J
J Virol; 2005 Jul; 79(14):9180-91. PubMed ID: 15994812
[TBL] [Abstract][Full Text] [Related]
14. A novel method for promoting heterologous protein expression in Escherichia coli by fusion with the HIV-1 TAT core domain.
Wu Y; Ren C; Gao Y; Hou B; Chen T; Zhang C
Amino Acids; 2010 Aug; 39(3):811-20. PubMed ID: 20213440
[TBL] [Abstract][Full Text] [Related]
15. The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication.
Accolla RS; Mazza S; De Lerma Barbaro A; De Maria A; Tosi G
Eur J Immunol; 2002 Oct; 32(10):2783-91. PubMed ID: 12355430
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HIV derived lentiviral production by TAR RNA binding domain of TAT protein.
Mi MY; Zhang J; He Y
Retrovirology; 2005 Nov; 2():71. PubMed ID: 16293193
[TBL] [Abstract][Full Text] [Related]
17. Engineering, cloning, and functional characterization of recombinant LIM mineralization protein-1 containing an N-terminal HIV-derived membrane transduction domain.
Sangadala S; Okada M; Liu Y; Viggeswarapu M; Titus L; Boden SD
Protein Expr Purif; 2009 Jun; 65(2):165-73. PubMed ID: 19284982
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of tat-mediated HIV-1-LTR transactivation and virus replication by sulfhydryl compounds with chelating properties.
Demirhan I; Chandra A; Sarin PS; Hasselmayer O; Hofmann D; Chandra P
Anticancer Res; 2000; 20(4):2513-7. PubMed ID: 10953320
[TBL] [Abstract][Full Text] [Related]
19. Anti-Tat and anti-HIV activities of trimers of n-alkylglycines.
Márquez N; Sancho R; Macho A; Moure A; Masip I; Messeguer A; Muñoz E
Biochem Pharmacol; 2006 Feb; 71(5):596-604. PubMed ID: 16405868
[TBL] [Abstract][Full Text] [Related]
20. Potent inhibition of HIV-1 gene expression and TAT-mediated apoptosis in human T cells by novel mono- and multitarget anti-TAT/Rev/Env ribozymes and a general purpose RNA-cleaving DNA-enzyme.
Unwalla H; Chakraborti S; Sood V; Gupta N; Banerjea AC
Antiviral Res; 2006 Nov; 72(2):134-44. PubMed ID: 16790281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
